(Repeats to attach to alerts)
GENEVA, Feb 9 (Reuters) - AstraZeneca's Chief
Executive said on Tuesday that the results of a study showing
its COVID-19 vaccine had little effect against mild disease were
concerning but stressed that it should work against severe
forms.
"It is of course a concern," Pascal Soriot said of the study
at a World Health Organization meeting. "Having said that the
patients in the study were patients with mild disease and we
believe the vaccine should still protect against severe
disease."
AstraZeneca is a major supplier to a WHO-backed
vaccine-sharing scheme called COVAX.
(Reporting by Emma Farge, John Miller and Michael Shields)
Astrazeneca (AZN)
